Surfing the MASH Tsunami

Send us Fan Mail Ian Rowe, Michelle Long and Manal Abdelmalek reveal what they consider the most important NAFLD/NASH stories of summer. Which NAFLD/NASH stories did they choose? The newly-appointed Professor Rowe discusses the importance of the FDA approval of the ELF test as a prognostic for cirrhosis. True to her epidemiological background, Professor Long reviews the prospective prevalence stud...

Send us Fan Mail Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting. This conversation looks at the Day Two sessions and the overall implications of the meeting. Paris NASH is a meeting for basic science and interdisciplinary thinking. While the first two conversations of this series focused specifically on one or two session...

Send us Fan Mail Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting. This conversation looks at sessions covering epidemiology, public response and clinical questions. Paris NASH is a meeting for basic science and interdisciplinary thinking. As Jörn Schattenberg reviews the first two sessions of the meeting, he covers both th...

Send us Fan Mail Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting. This conversation looks at the session covering fibrosis. Paris NASH is a meeting for basic science and interdisciplinary thinking. Since Stephen Harrison was drafted into co-chairing the session titled "Deep Dive into Fibrosis," he led this conver...

Send us Fan Mail Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting, an event with exciting scientific messages and insights. If you missed last week's Paris NASH meeting, you missed some exciting presentations featuring fresh, pivotal insights about Fatty Liver diseases and some new approaches to learning about this dis...

Send us Fan Mail Global Liver Institute President and CEO Donna Cryer joins Roger Green to discuss why recent EASL guidelines around use of non-invasive tests (NITs) in Fatty Liver diagnosis and disease tracking is such an important step for patients and treaters alike.  To Global Liver Institute President and CEO Donna Cryer, the recent EASL Guidelines on use of non-invasive testing (NITs) repres...

Send us Fan Mail Fatty Liver Foundation President Wayne Eskridge joins Louise Campbell and Roger Green to discuss why he is so enthusiastic about the FDA's recent approval of the ELF test as a prognostic test for cirrhosis.  To Fatty Liver Foundation President Wayne Eskridge, FDA's recent approval of Siemens's ELF test as prognostic for cirrhosis is only the first step in the proces...

Send us Fan Mail NASH kNOWledge President Anthony Villiotti joins Louise Campbell and Roger Green to highlight two recent publications about NAFLD/NASH prevalence (underestimated!) and patient awareness (miniscule!) and what that portends for the future,  To NASH kNOWledge President Anthony Villiotti, two recent publications reveal that conventional estimates of NAFLD and NASH prevalence in the US...

Send us Fan Mail Louise Campbell and Roger Green interview patients/patient advocates Donna Cryer, Wayne Eskridge and Anthony Villiotti about what each considers the biggest NAFLD story of the summer. The Biggest NAFLD/NASH story of the summer? Each had different ideas. To NASH kNOWledge President and Founder Tony Villiotti, the biggest story combined two recent publications that cross-validated t...

Send us Fan Mail Donna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021.  This conversation focuses on the current and potential impact of the Delta and future variants on clinical trial performance.   Seventeen months ago, Surfing the NASH Tsunami began as a podcast focused on how COVID-19 and the pandemic would affect NASH clinical trials...

Send us Fan Mail Donna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This conversation focuses on vaccine confusion (taking the flu vaccine, the meaning of full approval) and the importance of global COVID-19 vaccine equity and policies that support it. This conversation has several moments of debate, one around the likely strength of f...

Send us Fan Mail Donna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021.  This discussion focuses on the case for post-jab immunologic testing for compromised patients and goes on to explore what the US can learn from the UK's experience with the COVID-19 vaccine. Donna Cryer starts this episode by discussing the vital importance of co...

Send us Fan Mail Donna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This discussion focuses on the process of moving immunocompromised and transplant patients to the front of the booster dose queue. After Roger Green sets the preamble for this discussion of COVID-19 Delta variant and Fatty Liver Disease, Donna Cryer kicks the discussio...

Send us Fan Mail Donna Cryer joins the Surfers to discuss the different effects that the Delta Variant of COVID-19 is having on different stakeholders within the Fatty Liver community. What impact is the Delta Variant of COVD-19 having on NAFLD and NASH? Let us count the ways in this lively, fast-paced episode with Donna Cryer and the Surfers: 16:11 - Global Liver Institute's efforts to drive...

Send us Fan Mail Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation constitutes a call to action for the Surfers and our listeners.  In terms of cirrhosis and drug development, the earlier conversations identified two goals: Focus on NASH cirrhosis as a possible an easier and faster path to approval than the traditional "start with F2/3" appro...

Send us Fan Mail Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on how to drive a broader change in perspective. Once we accept the idea that cirrhosis can make an excellent target for drug development driven using non-invasive testing, the question is take the lead in bringing the appropriate initiative forward. Stephen Harrison points out...

Send us Fan Mail Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on why F4 might be a better target than F2/3. This conversation focuses on specific reasons that initiating drug development in cirrhosis might offer unique benefits against the traditional model. Stephen Harrison starts off by discussing changing views of which cirrhosis patien...

Send us Fan Mail Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on the unique challenges in treating NASH cirrhosis. This conversation focuses on challenges in treating patients with NASH cirrhosis and implications for drug development. Jörn Schattenberg begins by discussing several of the elements that make treating patients with NASH cirrh...

Send us Fan Mail Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis, which evolves into a discussion about how to drive NITs forward. Historically, NASH drug development strategy has started in advanced fibrosis with the goal of progressing to cirrhosis next. This episode suggests an entirely different approach. The episode starts by discussing the complexities of treatin...

Send us Fan Mail Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy. This conversation detours into health policy and screen fail rates before returning to consider the 2-5 year implications of FGF drug therapies. After a simple opening from Roger Green, this conversa...

Send us Fan Mail Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy. This conversation focuses on the roles fibroblast growth factors (FGFs) play in fat metabolism, appetite and other issues related to Fatty Liver disease.  After a simple opening from Roger Green, thi...

Send us Fan Mail Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy. This conversation focuses on FGF drug development to date. After a simple opening from Roger Green, this conversation includes 4 key elements: 1:05 - Roger Green discusses recent history of FGF agent...

Send us Fan Mail Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy. This discussion combines a discussion of the role Fibroblast Growth Factors (FGFs) play in the liver and human body in general, followed by a discussion of what this implies for drug development in g...

Send us Fan Mail Co-authors Ken Cusi and Stephen Harrison discuss reasons to be optimistic and activist about the multidisciplinary call to action regarding the coming NASH Epidemic while NASH kNOWledge President Anthony Villiotti, Global Liver Institute Director of Global Policy Andrew Scott and Roger Green share their unique personal perspectives and Louise Campbell comments separately. This con...

Send us Fan Mail Co-authors Ken Cusi and Stephen Harrison discuss critical success factors in the multidisciplinary call to action regarding the coming NASH Epidemic while NASH kNOWledge President Anthony Villiotti, Global Liver Institute Director of Global Policy Andrew Scott and Roger Green share their unique personal perspectives and Louise Campbell comments separately. This conversation starts...